- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8849
| Related Targets | Proteasome E3 Ligase DUB p97 SUMO E2 conjugating |
|---|---|
| Other E1 Activating Products | MLN4924 (Pevonedistat) TAK-243 (MLN7243) PYR-41 ML792 COH000 Pevonedistat hydrochloride Ubiquitin Antibody [J9C13] PYZD-4409 Atg7 Antibody [K21F3] NEDD8 Antibody [D22F6] |
|
In vitro |
DMSO
: 100 mg/mL
(197.42 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 506.51 | Formula | C21H23FN6O6S |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1848959-10-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCOC1=CC=CC(=C1C#CC2=C[N](C3OC(CN[S](N)(=O)=O)C(O)C3O)C4=C2C(=NC=N4)N)F | ||
| Targets/IC50/Ki |
NAE
(Cell-free assay) 0.955 nM
|
|---|---|
| In vitro |
TAS4464 selectively inhibits NAE relative to the other E1s UAE and SAE. This compound treatment inhibits cullin neddylation and subsequently induces the accumulation of CRL substrates such as CDT1, p27, and phosphorylated IkBa in human cancer cell lines. Cytotoxicity profiling reveals that it is highly potent with widespread antiproliferative activity not only for cancer cell lines, but also patient-derived tumor cells. |
| In vivo |
TAS4464 shows prolonged target inhibition in human tumor xenograft mouse models; weekly or twice a week administration of this compound led to prominent antitumor activity in multiple human tumor xenograft mouse models including both hematologic and solid tumors without marked weight loss. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02978235 | Terminated | Multiple Myeloma|NonHodgkin Lymphoma |
Taiho Oncology Inc. |
March 1 2017 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.